Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. more
Time Frame | JSPR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.36% | -2.28% | -0.57% |
1-Month Return | -9.65% | -3.98% | 1.2% |
3-Month Return | -9.45% | -9.71% | 7.56% |
6-Month Return | -15.37% | -3.39% | 11.44% |
1-Year Return | 385.85% | 3.69% | 28.47% |
3-Year Return | -77.66% | 3.78% | 29.51% |
5-Year Return | -79.02% | 39.76% | 90.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 6.20M | 13.51M | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":45.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 21.00K | 566.00K | 1.31M | 1.11M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":1.6,"profit":true},{"date":"2021-12-31","value":43.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.58,"profit":true}] |
Gross Profit | - | (21.00K) | (566.00K) | (1.31M) | (1.11M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2100000,"profit":false},{"date":"2021-12-31","value":-56600000,"profit":false},{"date":"2022-12-31","value":-131000000,"profit":false},{"date":"2023-12-31","value":-110800000,"profit":false}] |
Gross Margin | - | - | (9.13%) | (9.70%) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-9.13,"profit":false},{"date":"2022-12-31","value":-9.7,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 4.45M | 20.68M | 36.83M | 51.20M | 68.86M | [{"date":"2019-12-31","value":6.47,"profit":true},{"date":"2020-12-31","value":30.04,"profit":true},{"date":"2021-12-31","value":53.49,"profit":true},{"date":"2022-12-31","value":74.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (4.71M) | (20.68M) | (36.83M) | (51.20M) | (68.86M) | [{"date":"2019-12-31","value":-471000000,"profit":false},{"date":"2020-12-31","value":-2068300000,"profit":false},{"date":"2021-12-31","value":-3683300000,"profit":false},{"date":"2022-12-31","value":-5119600000,"profit":false},{"date":"2023-12-31","value":-6886100000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | 14.21M | 7.97M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":56.06,"profit":true}] |
Pre-Tax Income | (4.99M) | (31.67M) | (30.64M) | (37.69M) | (66.09M) | [{"date":"2019-12-31","value":-498700000,"profit":false},{"date":"2020-12-31","value":-3166900000,"profit":false},{"date":"2021-12-31","value":-3063700000,"profit":false},{"date":"2022-12-31","value":-3768500000,"profit":false},{"date":"2023-12-31","value":-6609300000,"profit":false}] |
Income Taxes | (277.00) | (38.45K) | (6.65M) | (13.51M) | (1.63M) | [{"date":"2019-12-31","value":-27700,"profit":false},{"date":"2020-12-31","value":-3845100,"profit":false},{"date":"2021-12-31","value":-665300000,"profit":false},{"date":"2022-12-31","value":-1351100000,"profit":false},{"date":"2023-12-31","value":-162800000,"profit":false}] |
Income After Taxes | - | - | - | (24.17M) | (64.47M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-2417400000,"profit":false},{"date":"2023-12-31","value":-6446500000,"profit":false}] |
Income From Continuous Operations | - | (6.48M) | (36.83M) | (51.20M) | (64.47M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-648070100,"profit":false},{"date":"2021-12-31","value":-3683300000,"profit":false},{"date":"2022-12-31","value":-5119600000,"profit":false},{"date":"2023-12-31","value":-6446500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.99M) | (31.67M) | (23.98M) | (24.17M) | (64.47M) | [{"date":"2019-12-31","value":-498700000,"profit":false},{"date":"2020-12-31","value":-3166900000,"profit":false},{"date":"2021-12-31","value":-2398400000,"profit":false},{"date":"2022-12-31","value":-2417400000,"profit":false},{"date":"2023-12-31","value":-6446500000,"profit":false}] |
EPS (Diluted) | (0.00) | 0.06 | (2.35) | (1.03) | (1.97) | [{"date":"2019-12-31","value":-0.17,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3916.67,"profit":false},{"date":"2022-12-31","value":-1716.67,"profit":false},{"date":"2023-12-31","value":-3283.33,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
JSPR | |
---|---|
Cash Ratio | 7.42 |
Current Ratio | 7.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
JSPR | |
---|---|
ROA (LTM) | -40.92% |
ROE (LTM) | -71.46% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
JSPR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
JSPR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.69 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Jasper Therapeutics Inc (JSPR) share price today is $21.4
Yes, Indians can buy shares of Jasper Therapeutics Inc (JSPR) on Vested. To buy Jasper Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JSPR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Jasper Therapeutics Inc (JSPR) via the Vested app. You can start investing in Jasper Therapeutics Inc (JSPR) with a minimum investment of $1.
You can invest in shares of Jasper Therapeutics Inc (JSPR) via Vested in three simple steps:
The 52-week high price of Jasper Therapeutics Inc (JSPR) is $31.01. The 52-week low price of Jasper Therapeutics Inc (JSPR) is $4.4.
The price-to-earnings (P/E) ratio of Jasper Therapeutics Inc (JSPR) is
The price-to-book (P/B) ratio of Jasper Therapeutics Inc (JSPR) is 3.69
The dividend yield of Jasper Therapeutics Inc (JSPR) is 0.00%
The market capitalization of Jasper Therapeutics Inc (JSPR) is $309.03M
The stock symbol (or ticker) of Jasper Therapeutics Inc is JSPR